Shattuck Labs
STTK on Nasdaq. Shattuck Labs develops antibody medicines for patients with inflammatory and immune diseases. Market value $652m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-7.01 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
Each dollar kept in the business earns -144 cents a year. Above 10 is good.
Quality score: 20 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$5.86 a share, 245% above its 1-year low
Over the past year the price has ranged from $1.70 to $8.33.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $30m | $652,000 | $2m | $6m | $1m |
| Operating margin | |||||
| Operating margin | -150.8% | -15848.0% | -5549.6% | -1408.3% | -5150.8% |
| Debt to equity | |||||
| Debt to equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares outstanding | |||||
| Shares outstanding | 0.04bn | 0.04bn | 0.05bn | 0.06bn | 0.10bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting checksSkipped: company is not yet profitable
- Debt0.00× equity
- Revenue growth, five yearsShrinking, 36.8% a year
- Buying back its own sharesNo, 137% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $15 million, compared with a loss of $12 million a year ago.
- It loses 5579 cents on each $1 of sales, compared with 2168 cents a year earlier.
- Over the past 12 months it spent $41 million more cash than it brought in, compared with $56 million a year earlier.
- 154% more shares than a year ago. Each share owns a bit less of the company.
- It has $63 million more cash than debt, up from $50 million a year ago.
- Sales did not grow on a year ago in any of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $3m |
| December 2024 | $0 |
| March 2025 | $0 |
| June 2025 | $0 |
| September 2025 | $1m |
| December 2025 | $0 |
| March 2026 | $0 |
| June 2026 | $0 |
| Quarter to | Amount |
|---|---|
| September 2024 | -$17m |
| December 2024 | -$19m |
| March 2025 | -$14m |
| June 2025 | -$12m |
| September 2025 | -$10m |
| December 2025 | -$13m |
| March 2026 | -$15m |
| June 2026 | -$15m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 5 March 2026
- Next quarterly (estimated, 10-Q)
- 10 November 2026
Who owns it
None of the long-term investors we follow own it. 100 funds in all.
Largest holders overall
- T. Rowe Price Investment Management$93mAdded
- Adage Capital Partners GP, L.L.C.$56mAdded
- Redmile Group$48mAdded
- Orbimed Advisors$44m
- Prosight Management, LP$41mAdded
- BlackRock$27mAdded
- Frazier Life Sciences Management, L.P.$26mNew
- NEXTBio Capital Management LP$26mAdded
- Deep Track Capital, LP$26mNew
- Vanguard Capital Management$22mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
6 investors own more than 5%.
- T. Rowe Price Investment Management, Inc.Passive investor15.3%+1.5 ptsSince 30 June 2026
- ORBIMED ADVISORS LLCPassive investorat least 10.0%0.0 pts(filed with 2 related holders)Since 11 June 2026
What they said
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in…
Read the filing - Redmile Group, LLCInsider or founderat least 9.9%0.0 pts(filed with 2 related holders)Since 15 July 2026
- Prosight Management, LPPassive investorat least 9.9%(filed with 4 related holders)Since 30 September 2025
- Adage Capital Management, L.P.Passive investorat least 9.8%(filed with 3 related holders)Since 31 December 2024
- Deep Track Capital, LPPassive investorat least 5.2%(filed with 2 related holders)Since 10 June 2026
- The Vanguard GroupPassive investorSold down below 5%Since 30 June 2025
- BlackRock, Inc.Passive investorSold down below 5%Since 30 June 2025
| Holder | Stake | Since | |
|---|---|---|---|
T. Rowe Price Investment Management, Inc. Passive investor | 15.3%+1.5 pts | 30 June 2026 | |
ORBIMED ADVISORS LLC Passive investor | at least 10.0%0.0 pts (filed with 2 related holders) | 11 June 2026 | What they saidThe Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in… Read the filing |
Redmile Group, LLC Insider or founder | at least 9.9%0.0 pts (filed with 2 related holders) | 15 July 2026 | |
Prosight Management, LP Passive investor | at least 9.9% (filed with 4 related holders) | 30 September 2025 | |
Adage Capital Management, L.P. Passive investor | at least 9.8% (filed with 3 related holders) | 31 December 2024 | |
Deep Track Capital, LP Passive investor | at least 5.2% (filed with 2 related holders) | 10 June 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 30 June 2025 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 June 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $250,000 of shares on the open market. 2 sold $591,850, $591,850 of it under preset trading plans.
- Shukla Abhinav A.Chief Technical OfficerSoldunder a preset trading plan
- Date
- 2 July 2026
- Shares
- 410
- Price
- $7.01
- Value
- $2,874
- Shukla Abhinav A.Chief Technical OfficerSoldunder a preset trading plan
- Date
- 1 July 2026
- Shares
- 100
- Price
- $7.07
- Value
- $707
- Shukla Abhinav A.Chief Technical OfficerSoldunder a preset trading plan
- Date
- 30 June 2026
- Shares
- 23,365
- Price
- $7.08
- Value
- $165,424
- Pandite Arundathy N.Chief Medical OfficerSoldunder a preset trading plan
- Date
- 30 June 2026
- Shares
- 30,000
- Price
- $7.01
- Value
- $210,300
- SIEGALL CLAY BDirectorBought
- Date
- 9 June 2026
- Shares
- 62,500
- Price
- $4.00
- Value
- $250,000
- Shukla Abhinav A.Chief Technical OfficerSoldunder a preset trading plan
- Date
- 12 May 2026
- Shares
- 2,032
- Price
- $7.01
- Value
- $14,244
- Pandite Arundathy N.Chief Medical OfficerSoldunder a preset trading plan
- Date
- 12 May 2026
- Shares
- 30,000
- Price
- $6.61
- Value
- $198,300
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 2 July 2026 | Shukla Abhinav A. Chief Technical Officer | Sold under a preset trading plan | 410 | $7.01 | $2,874 |
| 1 July 2026 | Shukla Abhinav A. Chief Technical Officer | Sold under a preset trading plan | 100 | $7.07 | $707 |
| 30 June 2026 | Shukla Abhinav A. Chief Technical Officer | Sold under a preset trading plan | 23,365 | $7.08 | $165,424 |
| 30 June 2026 | Pandite Arundathy N. Chief Medical Officer | Sold under a preset trading plan | 30,000 | $7.01 | $210,300 |
| 9 June 2026 | SIEGALL CLAY B Director | Bought | 62,500 | $4.00 | $250,000 |
| 12 May 2026 | Shukla Abhinav A. Chief Technical Officer | Sold under a preset trading plan | 2,032 | $7.01 | $14,244 |
| 12 May 2026 | Pandite Arundathy N. Chief Medical Officer | Sold under a preset trading plan | 30,000 | $6.61 | $198,300 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
- Sales have shrunk: 36.8% a year.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.